In a significant policy pivot aimed at tackling the nation’s declining birth rates and the prohibitive costs of family planning, the Trump administration announced a new proposed rule this past Monday. The regulation seeks to empower employers to offer standalone, supplemental health insurance specifically designed to cover fertility benefits, including in vitro fertilization (IVF), diagnostic testing, and genetic screening.
The move represents a strategic effort to address what the administration characterizes as a "fertility crisis," framing the struggle of American couples to conceive as both a personal hardship and a broader threat to national economic stability and security. While the administration touts the proposal as a flexible, market-based solution, the policy has ignited a complex debate among health economists, reproductive rights advocates, and business leaders regarding the long-term efficacy of "excepted benefits" in the American healthcare landscape.
The Core Proposal: Expanding Access Through "Excepted Benefits"
The proposed rule, jointly spearheaded by the Departments of Labor, Health and Human Services (HHS), and the Treasury, establishes a framework for employers to provide fertility-specific coverage that operates independently of major medical health insurance.
Under the current U.S. healthcare system, fertility treatments—particularly IVF—are frequently excluded from standard employer-sponsored plans. When they are included, coverage is often subject to strict limitations or geographic variability. The new rule would allow employers to treat fertility benefits similarly to how they currently treat standalone dental or vision insurance. By classifying these offerings as "limited excepted benefits," the government aims to bypass certain regulatory hurdles that apply to comprehensive medical plans, theoretically allowing companies to design, scale, and implement these benefits with greater agility.
The proposed coverage would be robust, extending to lab tests, hormonal medications, genetic testing, and the IVF procedure itself. Furthermore, it would address conditions that frequently impact fertility, such as polycystic ovary syndrome (PCOS) and endometriosis. To ensure a significant level of support, the rule stipulates a lifetime benefit cap of $120,000 per participant, a figure that is set to be adjusted for inflation beginning in 2028.
A Chronology of Policy Development
The path to this week’s announcement began in earnest during the 2024 presidential campaign, when then-candidate Donald Trump made fertility care and IVF access a central tenet of his healthcare platform.
- February 2025: President Trump signed an executive order directing federal agencies to formulate policy recommendations specifically aimed at reducing the financial burden of IVF. This order signaled a shift toward administrative action, as the administration sought ways to move the needle without relying on a divided Congress.
- Spring/Summer 2025: The Department of Health and Human Services, alongside the Treasury and Labor departments, began reviewing the legal landscape surrounding "excepted benefits." During this period, the administration also launched "TrumpRX," an initiative aimed at providing discounted access to specific medications used in fertility treatments.
- September 2025: The formal proposal was released. The administration now enters a 60-day public comment period following its publication in the Federal Register. Once the comment period closes and final adjustments are made, the rule will move toward implementation, though experts caution that actual patient access may be months away.
Supporting Data: The Economic Reality of IVF
The necessity for this rule is rooted in the high financial barriers to entry for reproductive medicine. According to data from the Department of Health and Human Services, a single cycle of IVF typically costs between $15,000 and $20,000. Because success is rarely guaranteed on the first attempt, many couples find themselves facing total costs that can easily spiral into the tens of thousands.
The KFF (Kaiser Family Foundation) reports that approximately 25% of large companies currently offer some form of voluntary fertility coverage, though the scope of these benefits varies wildly. Meanwhile, at least a dozen states have enacted mandates requiring private insurance to cover some level of fertility care, creating a patchwork system of access that leaves millions of Americans—particularly those in states without mandates or those working for small to mid-sized businesses—without any financial buffer.
Health and Human Services Secretary Robert F. Kennedy Jr. underscored the urgency of the situation during the announcement, citing the steady decline in U.S. birth rates. "We are facing a fertility crisis," Kennedy remarked. "It is a threat not only to our economy but to our national security."
Official Responses and Stakeholder Perspectives
The reception to the proposal has been cautiously optimistic in some circles, while others remain skeptical about its practical implementation.
Sean Tipton, chief advocacy and policy officer for the American Society for Reproductive Medicine, acknowledged the potential value of the proposal, noting that a $120,000 lifetime cap is substantial enough to facilitate meaningful treatment. However, Tipton also pointed to the inherent limitations of the plan, noting that it remains optional for employers. "It’s unclear what incentives employers would have to offer this benefit," Tipton noted, adding that his organization continues to lobby Congress for a federal mandate that would require universal IVF coverage across all plans, including those under the Affordable Care Act.
Public policy experts, such as Wesley Yin of the University of California, Los Angeles, highlight the trade-offs of the "excepted benefit" classification. While this classification allows for nimbler, cheaper plans by exempting them from many federal health plan requirements, it also creates potential for inequity. "Companies may offer the benefit only for higher-income professionals," Yin warned, noting that the lack of regulation could lead to a two-tiered system where fertility access becomes a perk of elite employment rather than a standard benefit of the workforce.
Implications: Will Costs Actually Decline?
The ultimate goal of the policy—lowering costs for families—remains the subject of intense debate among healthcare economists.
Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University, notes that the success of any insurance pool depends on the cross-subsidization of risk. In traditional comprehensive plans, the premiums of healthy individuals help cover the costs of those requiring medical care. In a standalone, optional fertility plan, those who are not actively seeking fertility treatment are unlikely to opt in.
"Without any subsidization from the employer or from people who are not using these services, this could mean that for many people, they might as well just pay out of pocket," Corlette explained. Furthermore, she raised a critical concern: employers currently providing fertility coverage as part of their comprehensive medical insurance might move that benefit into a standalone, less-regulated plan to cut costs, potentially shifting the financial burden onto the employees themselves.
Usha Ranji of KFF’s Women’s Health Policy Program agreed that while any assistance with out-of-pocket costs is a step in the right direction, the structural design of the plan is critical. "Any assistance can be helpful, but we must ensure that these plans don’t inadvertently create new hurdles for the very people they are intended to help," she said.
The Path Forward: Administrative vs. Legislative Action
A key takeaway from this announcement is the administration’s reliance on executive authority to bypass a gridlocked Congress. Because the legal framework for "excepted benefits" was established decades ago, amending these definitions to include fertility care does not require new legislation.
For the Trump administration, this is the "appeal" of the rule. It allows for immediate action in a policy area that has become a political lightning rod. However, critics argue that administrative rules are inherently fragile; they can be reversed by future administrations and lack the permanence and broader scope of congressional law.
As the 60-day comment period approaches, the administration will face pressure to clarify how it plans to incentivize employers to adopt these benefits. Without tax credits, subsidies, or mandates, the program relies entirely on the voluntary participation of the private sector. Whether this initiative will serve as a foundational step toward universal fertility access or remain an underutilized, niche offering will largely depend on the willingness of American corporations to view reproductive health as a critical investment in their workforce.
For now, the proposal stands as a bold, if untested, attempt to address the intersection of family policy, corporate benefits, and the declining American birth rate. For the thousands of families struggling with the high price of IVF, the coming months will be a waiting game to see if this administrative maneuver translates into lower bills at the clinic.
